Atrial Fibrillation Clinical Trial
— DEEPOfficial title:
Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach for Treatment of Subjects With Persistent or Long Standing Persistent Atrial Fibrillation With Radiofrequency Ablation
Verified date | March 2023 |
Source | AtriCure, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients presenting with Persistent Atrial Fibrillation or Longstanding Persistent Atrial Fibrillation
Status | Active, not recruiting |
Enrollment | 220 |
Est. completion date | December 2027 |
Est. primary completion date | November 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Symptomatic Persistent Atrial Fibrillation or Longstanding Persistent Atrial Fibrillation refractory to a minimum of one Class I or Class III AADs. Exclusion Criteria: 1. AF >10 years. 2. Refractory hypertension, defined as systolic (>150 mm Hg) or diastolic (> 90 mm Hg) blood pressure that remains uncontrolled despite sustained therapy 3. History of pulmonary hypertension 4. Pulmonary vein stenosis in one or more of the pulmonary veins 5. EP catheter ablation procedure to treat atrial fibrillation within 3 months 6. Undergone prior cardiothoracic surgery, previous thorax trauma which resulted in a pneumothorax or hemothorax. 7. Sleep apnea, home oxygen therapy, moderate to severe COPD, (FEV1/FVC < 70% predicted) or patient is considered intolerant to single lung ventilation. 8. NYHA Class IV heart failure. 9. Uncorrected, reversible cause(s) of atrial fibrillation, or is currently being treated for arrhythmias other than atrial fibrillation (AF) or atrial flutter. 10. Documented history of previous catheter ablation with perforation, history of pericarditis, pericardial effusion, or tamponade. 11. Structural heart disease requiring surgical treatment (i.e. valve disease requiring repair or replacement within 12 months following surgical ablation procedure). 12. CAD requiring intervention (either surgical, i.e. CABG, or catheter). 13. Ejection fraction < 30% 14. Measured left atrial diameter > 5.5 cm 15. Stroke/cerebrovascular accident (CVA) within previous six months, carotid artery stenosis greater than 80%. 16. BMI is >40 17. Thrombus in the left atrium or the left atrial appendage, determined by echocardiography (either at baseline TTE (or equivalent diagnostic test) or intraoperative TEE). 18. Blood dyscrasia or clotting disorder (i.e. Idiopathic Thrombocytopenic Purpura [ITP] or Thrombotic Thrombocytopenic Purpura [TTP]). 19. Contraindication to anticoagulation that in the opinion of the investigator poses undue risk to the patient from participating in the endocardial EP procedure. 20. Documented thromboembolism within the previous six months prior to signing informed consent. 21. Has the following atrial myxoma, mural thrombus or mural tumor. 22. A condition or congenital anomaly which prevents required surgical or catheter access. 23. A co-morbid condition that, in the opinion of the investigator, poses undue risk of general anesthesia or port access cardiac surgery. 24. Currently abusing drugs or alcohol. 25. Currently or has participated in a clinical study in the last 3 months prior to signing informed consent. 26. A psychological disorder that could interfere with provision of informed consent, completion of tests, therapy, or follow-up. 27. A condition that, in the opinion of the investigator, may jeopardize the patient's well-being and/or the soundness of this clinical study. 28. Pre-existing esophageal condition that required (or requires) endoscopic therapy or surgical treatment. |
Country | Name | City | State |
---|---|---|---|
Belgium | Universitair Ziekenhuis Brussel (UZ Brussels) | Brussels | |
Netherlands | Academic Medical Center (AMC) | Amsterdam | |
United States | Saint Alphonsus Regional Medical Center | Boise | Idaho |
United States | The Christ Hospital | Cincinnati | Ohio |
United States | Tri Health Hosptial - Good Samaritan and Bethesda North Hospitals | Cincinnati | Ohio |
United States | Shands at the University of Florida | Gainesville | Florida |
United States | Pinnacle Health | Harrisburg | Pennsylvania |
United States | Long Beach Memorial Medical Center | Long Beach | California |
United States | Cedars-Sinai Heart Institute | Los Angeles | California |
United States | Sentara Cardiovascular Research Institute | Norfolk | Virginia |
United States | Alta Bates Sutter Medical Center, East Bay Hospital | Oakland | California |
United States | Orlando Heart Institute | Orlando | Florida |
United States | Virginia Commonwealth University | Richmond | Virginia |
United States | St. Helena Hospital, Adventist Heart Institute | Saint Helena | California |
United States | Sarasota Memorial Hospital | Sarasota | Florida |
United States | Stanford University Department of CV medicine | Stanford | California |
United States | Aspirus Research Institute | Wausau | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
AtriCure, Inc. |
United States, Belgium, Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Freedom from any documented AF, atrial flutter, or atrial tachycardia lasting >30 seconds in duration through the 12 month follow-up visit in the absence of Class I or III AADs (with the exception of previously failed | 6 months post the Endocaridal Ablation Procedure through the 12 month follow-up visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |